Side-by-side · Research reference

AHK-CuvsDermorphin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BAnimal-StrongHUMAN-REVIEWED20/47 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

01Mechanism of Action

Parameter

AHK-Cu

Dermorphin

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Feedback intact?

—

N/A — exogenous opioid agonist

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Antibody development

—

Site-directed antibodies produced for detection and purificationCucumel 1996

02Dosage Protocols

Parameter

AHK-Cu

Dermorphin

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

—

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Animal studies · In vitro assays

Duration

Not established — cosmetic protocols typically 8–12 weeks

—

Legal status

—

Controlled substance in many jurisdictions · Research only

Not approved for human use.

Animal research (ICV)

—

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

Detection limit (doping)

—

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

Duration of action

—

10–120 minutes (dose-dependent, intrathecal)

Human toxicity

—

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

04Side Effects & Safety

Parameter

AHK-Cu

Dermorphin

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Opioid effects

—

Respiratory depression, sedation, euphoria, tolerance, dependence risk

CNS effects

—

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

Kambô ritual toxicity

—

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

Peripheral effects

—

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

Receptor selectivity caveat

—

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

Proteolytic stability

—

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

05Administration Protocol

Parameter

AHK-Cu

Dermorphin

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

—

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Dermorphin

— no documented stacks